Comments
Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, announced commencement of a Phase-II trial investigating Zyani1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).
Zyani1 is an oral small molecule designed to increase natural production of haemoglobin and RBCs in anaemic patients. It has been shown to improve iron mobilisation and has the potential to reduce or eliminate the need for iron supplementation, said Pankaj Patel, Chairman and Managing Director, in a statement here.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.